A Review of Microneedles – Elevation to TDDS Approach and Function in Management of Psoriasis
Novel drug delivery system offers several advantages which could outweigh the benefits of other drug delivery system. The transdermal drug delivery system being one of them offers supremacy by by-passing the first pass metabolism which eventually helps in eradication of gastrointestinal irritation. The first patent for microneedles was field in 1970’s, researchers on utilizing microneedles as a drug delivery system has progress significantly. This review aims to provide background on microneedles, clinical benefits and function of microneedles. The microneedle method is much more superior to those traditional transdermal delivery ways because of advantage such as invasive painless, convenience and improves patient compliance. Every type of microneedles has different advantages according to their unique properties and designs. We developed a dissolving microneedle (MN) patch made of hyaluronic acid (HA) with excellent water solubility, biocompatibility and mechanical properties. The traditional therapeutic method is diverse embracing topical drugs, systemic drugs, physical therapy etc. with the limitation of present drug, the demand for new delivery method for psoriasis is in the spotlight. The major drawback of the transdermal drug delivery system is the hindrance created via skin into the systemic circulation. Thus in order to overcome this hurdle a replacement to this type of novel drug delivery system. One of the best pharmaceutical dosage form for those patients. They cannot take medicaments orally. TDDS established itself as an integral part of NDDS.
2. Bhowmik D, Chiranjib, Chandira M, Jayakar B, Sampath KP. Recent advances in transdermal drug delivery system. Int. J Pharm Tech Res. 2010; (1):68-67.
3. Kumar A, Pullankandam N, Prabhu SL, Gopal V. Transdermal drug delivery system: an overview. Int J Pharm Sci. Review Res. 2010; 3(2):49-54.
4. Rani S, Saroha K, Syan N, Mathur P. Transdermal patches a successful tool in . transdermal drug delivery system. Plegia Res. Lib. 2011; 2(5):17-29.
5. Kumar KPS, Bhowmik D, Chiranji BB, Chandira RM. Transdermal drug delivery system- a novel drug delivery system and its market scope and opportunities. Int. J Pharm Bio Sci. 2010; 1(2):1-12.
6. Dhawan S, Aggarawal G. Development, fabrication and evaluation of transdermal drug delivery system- a review. Pharm info. Net. 2009: 1-25.
7. Wang M, Hu L, Xu C. Recent advances in the design of polymeric microneedles for transdermal drug delivery and biosensing. Lab Chip, 2017; 17(8):1373-87.
8. Durah S, Sharma M, Wen J. Recent advances in microneedle based drug delivery: Special emphasis on its use in paediatric population. Eur J Pharm Biopharm, 2019; 136:48-69
9. Langer R. Drugs on target. Science 2001; 293:58-59.
10. Davis SP, Landis BJ, Adams ZH, et al. Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force. J Biomech 2004; 37:1155-63.
11. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. Control Release 2007; 117:227-237.
12. Avis KE et al. Pharmaceutical Dosage Forms: Parental Modification, 2nd. New York: Marcel Dekker Inc, 1992.
13. Martanto W et al. Transdermal delivery of insulin using microneedles in vivo. Pharm Res 2004; 21:947-952.
14. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Delivery Rev 2004; 56:581-587.
15. Nicolus B, Leroux JC.The journey of a drug carrier in the body: a anatomo-physiological perpectives. J Control Release 2012; 161:152-163.
16. Mark RP, Robert L, Transdermal drug delivery. Nat Biotechnol 2008; 26:1261-1268.
17. Gerstel MS, Place VA. Drug delivery device. United State Patent 1976; US3,964-482
18. Kaushik S, Hord AH, Denson DD, McAllister DV, Smitra S, Allen MG, Prausnitz MR. Lack of pain associated wiyh microfabricated microneedles. Anesth Analg, 2001; 92(2):502-4.
19. Donnelly RF et al. Design, optimization and characterization of polymeric microneedle arrays prepared by a novel laser based micromoulding technique. Pharm Res 2011; 28:41-57.
20. Widera G et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 2006; 24:1653-1664.
21. McAllister DV et al. Microfabricated microneedles for gene and drug delivery. Annu Rev Biomed Eng 2000; 2; 289-313.
22. Chu LY, Ye L, Dong K, Yang C. Enhanced stability of inactivated influenza vaccine encapsulated in dissolving patches. Phaem Res 2016; 33(04):868-878.
23. . Kim YC, Park JH, Prausnitz MR. Microneedle for drug and vaccine delivery. Adv Drug Deliv Rev 2012; 64:1547-68.
24. R.F.Donnelly, T.R.Raj Singh and A.D.Woolfson, Drug Deliv, 2010; 17,187-207.
25. Escobar-Chavez JJ, Bonilla-Martinez D, Villegas-Gonzalez MA, et al. Microneedle: valuable physical enhancer to increase TDDS .J Clin pharmacol 2011; 51:964-77.
26. Kaur M, Ita KB, Popova IE. Microneedle assisted delivery of verapamil hydrochloride, amlodipine besylate. Eur J Pharm Biopharm, 2014; 86(2):284-91.
27. Maranto W, Davis SP, Holiday NR, Wang J. Transdermal delivery of insulin using microneedle in vivo. Pharm Res, 2004; 21(6):947-52.
28. Devin VM, Ping MW, Shawn PD. Microfabricated needles for transdermal delivery of macromolecules & nanoparticles. Proc Natl Acad Sci USA 2003; 100:13755-13760.
29. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery . J Control Release, 2007a; 117(2):227-37.
30. Cormier M, Johnson B, Ameri M, Nyam K, Libiran L, Zhang D, Daddona P. Transdermal delivery of desmopressin using coated microneedle array patch system. J Control Rel. 2004; 97:503-11.
31. Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterial, 2008; 29(13):2113-24.
32. Sullivan SP, Murthy N, Prausnitz MR. Minimally invasive protein delivery with rapidly dissolving polymer microneedle. Adv Mater. 2008; 20:933-938.
33. Naik A et al. Transdermal rug delivery: overcoming the skin barrier function. Pharm Sci Technol Today 2000; 3:318-326.
34. Wilke N et al. Silicon microneedle electrode array with temperature monitoring for electroporation. Sens Actuators 2005; 123:319-325.
35. Chen B et al. Sonophoretic enhanced microneedle array (SEMA) improving efficiency of transdermal drug delivery. Sens Actuators B Chem 2010; 145:54-60.
36. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008; 26:1261-1268.
37. Lin W et al. Transdermal delivery of antisense oligonucleotides with microprojection patch (Maacroflux) technology. Pharm Res 2001; 18:1789-1793.
38. Zahn JD et al. Continuous on clip micropumping for microneedle enhanced drug delivery. Biomed Microdevices 2004; 6:183-190.
39. Martanto W, Davis SP, Holiday NR, Wang J, Gill HS. Transdermal delivery of insulin using microneedles in vivo. Pharm Res, 2004; 21(6):947-52.
40. Pettis RJ, Harvey AJ. Microneedle delivery:clinical studies and emerging medical applications. Ther Deliv, 2012; 3(3):357-71.
41. Smart WH, Subramanian K. The use of silicon microfabrication technology in painless blood glucose monitoring Diabetes Technol Ther, 2000; 2(4):549-59.
42. Caudil CL, Perry JL, Tians S, Luft JC. Spatially controlled coating continuous liquid Interface production microneedles for transdermal protein delivery. J Control Release, 2018; 284:122-32.
43. Dogra S, Yadav S, Sarangal R. Microneedles for acne scars in A sian skin type: an effective low cost treatment modality. J Cosmetic Dermatol, 2014; 13(3); 180-7.
44. Pettis RJ, Harvey AJ. Microneedles delivery: clinical syudies and emerging medical application. The Deliv, 2012; 3(3):357-71.
45. P.de la Cueva Dobao, J. Notario, C. Ferrandiz, J. L. Lopez Estebaranz, I. Alarcon, S.Sulleiro, J. Borras, E. Dauden, J.M. Carrascosa; 2019; 33,1214-1223.
46. H. Marwah, T. Garg, A.K.Goyal and G.Rath, Drug Deliv, 2016; 23,564-578.
47. H.L.Richards, D.G.Fortune, T.M.O,Sullivan, C.J.Main and C.E.M.Griffiths, J.Am.Acad. Dermatol, 1999; 41,581-583.
48. A.Menter, A.Gottlieb, S.R.Feldam, A.S. Van Voorhees, C.L. Leonardi, C.A. Elmets, J.Am. Acad. Dermatol, 2008, 58,826-850.
49. H.X. Nguyen and A.K. Banga, Pharm. Res, 2018; 35:68.
50. J.H.Lee, Y.S.Jung, G.M.Kim and J.M.Bae, Br. J. Dermatol, 2018; 178,e24-e25.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).